Literaturverzeichnis

Bisphosphonat-assoziierte Osteonekrose der Maxilla

Michael M. Bornstein¹, Kaspar Oberli¹, Edouard Stauffer², Daniel Buser²¹Klinik für Oralchirurgie und Stomatologie, Zahnmedizinische Kliniken der Universität Bern
²Institut für Pathologie, Universität Bern
ABU-ID MH, AÇIL Y, GOTTSCHALK J, KREUSCH T: Bisphosphonatassoziierte Osteonekrose des Kiefers. Mund Kiefer Gesichtschir 10: 73-81 (2006)

BAXTER JC, FATTORE L: Osteoporosis and osseointegration of implants. J Prosthodont 2: 120-125 (1993)

BORNSTEIN M, FILIPPI A, BUSER D: Früh- und Spätfolgen im intraoralen Bereich nach Strahlentherapie. Schweiz Monatsschr Zahnmed 111: 61-73 (2001)

BORNSTEIN M, BUSER D, FILIPPI A: Konzepte zur Prophylaxe und Therapie strahlungsbedingter Nebenwirkungen. Schweiz Monatsschr Zahnmed 111: 962-977 (2001)

BUSER D, VON ARX T, TEN BRUGGENKATE CM, WEINGART D: Basic surgical principles with ITI implants. Clin Oral Impl Res 11 (Suppl.): 59-68 (2000)

DAO TT, ANDERSON JD, ZARB GA: Is osteoporosis a risk factor for osseointegration of dental implants? Int J Oral Maxillofac Impl 8: 137-144 (1993)

DELMAS PD: The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 17: 462-466 (2005)

FARRUGIA MC, SUMMERLIN DJ, KROWIAK E, HUNTLEY T, FREEMAN S, BORROWDALE R, TOMICH C: Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 116: 115-120 (2006)

FICARRA G, BENINATI F, RUBINO I, VANNUCCHI A, LONGO G, TONELLI P, PINI PRATO G: Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 32: 1123-1128 (2005)

FILIPPI A: Osteoradionekrose des Kieferknochens durch Prothesendruckstellen. Quintessenz 44: 963-967 (1993)

FILIPPI A: Komplikationen nach Zahnentfernung im bestrahlten Kieferknochen. Quintessenz 45: 1199-1206 (1994)

FLEISCH H: Osteoporosis. In: Fleisch H: Bisphosphonates in bone disease. From the laboratory to the patient. Academic Press, San Diego, pp 123-159 (2000)

FOURNIER P, BOISSIER S, FILLEUR S, GUGLIELMI J, CABON F, COLOMBEL M, CLÉZARDIN P: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: 6538-6544 (2002)

GASS M, DAWSON-HUGHES B: Preventing osteoporosis-related fractures: an overview. Am J Med 119: 3S-11S (2006)

HELLSTEIN JW, MAREK CL: Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63: 682-689 (2005)

HORTOBAGYI GN, THERIAULT RL, LIPTON A, PORTER L, BLAYNEY D, SINOFF C, WHEELER H, SIMEONE JF, SEAMAN JJ, KNIGHT RD, HEFFERNAN M, MELLARS K, REITSMA DJ: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16: 2038-2044 (1998)

HUBNER RA, HOUSTON SJ: Bisphosphonates' use in metastatic bone disease. Hosp Med 66: 414-419 (2005)

LEVIN L, BRYSON EC, CAPLAN D, TROPE M: Effect of topical alendronate on root resorption of dried replanted dog teeth. Dent Traumatol 17: 120-126 (2001)

LUTOSA-PEREIRA A, GARCIA RB, DE MORAES IG, BERNARDINELI N, BRAMANTE CM, BOTOLUZZI EA: Evaluation of the topical effect of alendronate on the root surface of extracted and replanted teeth. Microscopic analysis on rats' teeth. Dent Traumatol 22: 30-35 (2006)

MARX RE: Osteoradionecrosis: A new concept of its pathophysiology. J Oral Maxillofac Surg 41: 283-288 (1983)

MARX RE: Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115-1118 (2003a)

MARX RE, STERN D: Oral and Maxillofacial Pathology. A rationale for diagnosis and treatment. Quintessence Publishing Co, Inc, Chicago, pp 36-38 (2003b)

MATHOO JM, CRANNEY A, PAPAIOANNOU A, ADACHI JD: Rational use of oral bisphosphonates for the treatment of osteoporosis. Curr Osteoporos Rep 2: 17-23 (2004)

MERIGO E, MANFREDI M, MELETI M, CORRADI D, VESCOVI P: Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 34: 613-617 (2005)

MELO MD, OBEID G: Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy. Strategies for prevention and early recognition. J Am Dent Assoc 136: 1675-1681 (2005)

MIGLIORATI CA: Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21: 4253-4254 (2003)

MIGLIORATI CA, SCHUBERT MM, PETERSON DE, SENEDA LM: Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging oral complication of supportive cancer therapy. Cancer 104: 83-93 (2005a)

MIGLIORATI CA, CASIGLIA J, EPSTEIN J, JACOBSEN PL, SIEGEL MA, WOO SB: Managing the care of patients with bisphosphonate-associated osteonecrosis. An American Academy of Oral Medicine position paper. J Am Dent Assoc 136: 1658-1668 (2005b)

MILLER PD: Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Therapeutics 27: 361-376 (2005)

PERRIER M, MOELLER P: L' ostéoradionécrose: Une revue de la littérature. Schweiz Monatsschr Zahnmed 104: 271-277 (1994)

PALOMO L, BISSADA N, LIU J: Bisphosphonate therapy for bone loss in patients with osteoporosis and periodontal disease: clinical perspectives and review of the literature. Quintessence Int 37: 103-107 (2006)

REDDY MS, GEURS NC, GUNSOLLEY JC: Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A sytematic review. Ann Periodontol 8: 12-37 (2003)

REUTHER T, SCHUSTER T, MENDE U, KÜBLER A: Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumor patients - a report of a thirty year retrospective review. Int J Oral Maxillofac Surg 32: 289-295 (2003)

RODAN GA, FLEISCH HA: Bisphosphonates: mechanisms of action. J Clin Invest 97: 2692-2696 (1996)

ROGERS MJ, WATTS DJ, RUSSELL RGG: Overview of bisphosphonates. Cancer 80: 1652-1660 (2004)

RUGGIERO SL, MEHROTRA B, ROSENBERG TJ, ENGROFF SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527-534 (2004)

SARATHY AP, BOURGEOIS SLJR, GOODELL GG: Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod 31: 759-763 (2005)

SCHIRMER I, PETERS H, REICHART PA, DÜRKOP H: Bisphosphonate und Osteonekrosen im Kieferbereich. Mund Kiefer GesichtsChir 9: 239-245 (2005)

STARCK WJ, EPKER BN: Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. In J Oral Maxillofac Impl 10: 74-78 (1995)

TENENBAUM HC, SHELEMAY A, GIRARD B, ZOHAR R, FRITZ PC: Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other theapeutic/diagnostic uses. J Periodontol 73: 813-822 (2002)

VANNUCCHI AM, FICARRA G, ANTONIOLI E, BOSI A: Osteonecrosis of the jaws associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 128: 738 (2005)

WANGERIN K, HOFFMEISTER B, RANDZIO G: Zahnärztliche Chirurgie im bestrahlten Kiefer. Dtsch Zahnärztl Z 41: 444-448 (1986)

WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHING U, LOCKER GJ, SEVELDA U, ZIELINSKI CC, STEGER GG: Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome. Support Care Cancer 12: 678-681 (2004)

WOOD J, BONJEAN K, RUETZ S, BELLAHCÈNE A, DEVY L, FOIDART JM, CASTRONOVO V, GREEN JR: Novel antiangiogenic effects of bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055-1061 (2002)